Kaposi's sarcoma in pregnancy two case reports

1971 ◽  
Vol 58 (8) ◽  
pp. 577-579 ◽  
Author(s):  
J. F. Taylor ◽  
A. C. Templeton ◽  
S. Kylwazi ◽  
A. Lubega
Keyword(s):  
Kaposi's Sarcoma ◽  
Case Reports ◽  
Kaposi’S Sarcoma ◽  
In Pregnancy

scholarly journals HIVNegative Disseminated Cutaneous Kaposi’s Sarcoma: Three Case Reports.

2017 ◽  
Vol 02 (01) ◽  
Author(s):  
Ezgi Ozkur ◽  
Mehmet Salih Gurel ◽  
Sumeyre Seda Ertekin ◽  
Ayse Esra Koku Aksu ◽  
Cem Leblebici
Keyword(s):  
Kaposi's Sarcoma ◽  
Case Reports ◽  
Kaposi’S Sarcoma

scholarly journals The HIV Protease Inhibitor Nelfinavir Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication In Vitro

2011 ◽  
Vol 55 (6) ◽  
pp. 2696-2703 ◽  
Author(s):  
Soren Gantt ◽  
Jacquelyn Carlsson ◽  
Minako Ikoma ◽  
Eliora Gachelet ◽  
Matthew Gray ◽  
...  
Keyword(s):  
Inhibitory Activity ◽  
Kaposi's Sarcoma ◽  
Primary Effusion Lymphoma ◽  
Case Reports ◽  
Kaposi’S Sarcoma ◽  
Second Primary ◽  
Content Type ◽  
Kaposi's Sarcoma Associated Herpesvirus ◽  
Kaposi’S Sarcoma Associated Herpesvirus

ABSTRACTKaposi's sarcoma (KS) is the most common HIV-associated cancer worldwide and is associated with high levels of morbidity and mortality in some regions. Antiretroviral (ARV) combination regimens have had mixed results for KS progression and resolution. Anecdotal case reports suggest that protease inhibitors (PIs) may have effects against KS that are independent of their effect on HIV infection. As such, we evaluated whether PIs or other ARVs directly inhibit replication of Kaposi's sarcoma-associated herpesvirus (KSHV), the gammaherpesvirus that causes KS. Among a broad panel of ARVs tested, only the PI nelfinavir consistently displayed potent inhibitory activity against KSHVin vitroas demonstrated by an efficient quantitative assay for infectious KSHV using a recombinant virus, rKSHV.294, which expresses the secreted alkaline phosphatase. This inhibitory activity of nelfinavir against KSHV replication was confirmed using virus derived from a second primary effusion lymphoma cell line. Nelfinavir was similarly found to inhibitin vitroreplication of an alphaherpesvirus (herpes simplex virus) and a betaherpesvirus (human cytomegalovirus). No activity was observed with nelfinavir against vaccinia virus or adenovirus. Nelfinavir may provide unique benefits for the prevention or treatment of HIV-associated KS and potentially other human herpesviruses by direct inhibition of replication.

scholarly journals Successful Treatment of Kaposi's Sarcoma with a Combination of Antiviral Drug Therapy and Chemotherapy: Two Case Reports

1998 ◽  
Vol 27 (6) ◽  
pp. 1558-1558 ◽  
Author(s):  
Sékéné Badiaga ◽  
Philippe Parola ◽  
Christine Zandotti ◽  
Philippe Brouqui
Keyword(s):  
Drug Therapy ◽  
Successful Treatment ◽  
Kaposi's Sarcoma ◽  
Case Reports ◽  
Antiviral Drug ◽  
Kaposi’S Sarcoma

scholarly journals An Unusual Case of Invasive Kaposi’s Sarcoma with Primary Effusion Lymphoma in an HIV Positive Patient: Case Report and Literature Review

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Alexandra Millet ◽  
Sanmeet Singh ◽  
Genelle Gittens-Backus ◽  
Kim Ann Dang ◽  
Babak Shokrani
Keyword(s):  
African American Male ◽  
Kaposi's Sarcoma ◽  
Unusual Case ◽  
Primary Effusion Lymphoma ◽  
Case Reports ◽  
Kaposi’S Sarcoma ◽  
Distinct Pattern ◽  
Hiv Positive ◽  
Pancreatic Involvement ◽  
Organ Systems

We report a case of AIDS-related Kaposi’s sarcoma (KS) with Primary Effusion Lymphoma (PEL) in a 28-year-old, African American male. Kaposi’s sarcoma is an AIDS defining disease and typically will disseminate early in the course of the disease affecting the skin, mucous membranes, gastrointestinal tract, lymph nodes, and lungs. This case reports an unusual presentation of the disease along with primary effusion lymphoma. Although the most common organ systems affected by KS are the respiratory and the gastrointestinal systems, the lungs of this patient did not show any evidence of KS. Additionally, the patient demonstrates the rarely seen liver and unique pancreatic involvement by KS along with unusual synchronous bilateral pleural and peritoneal cavity involvement by PEL, adding to the distinct pattern of invasive AIDS-related Kaposi’s sarcoma.

Cutaneous Kaposi’s sarcoma in an HIV-negative patient with Crohn’s disease on thiopurine immunosuppression

2021 ◽  
Vol 14 (11) ◽  
pp. e245321
Author(s):  
Roghan Donohue Colbert ◽  
Daniel Gaya ◽  
Gordon Hale ◽  
William Rickaby
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Kaposi's Sarcoma ◽  
Case Reports ◽  
Immune Therapy ◽  
Kaposi’S Sarcoma ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Collaborative Discussion ◽  
Light Area

We present the rare case of a 61-year-old man with Crohn’s disease who developed a cutaneous Kaposi’s sarcoma in the setting of long-term treatment with 6-mercaptopurine. Deciding on the best course of management provided a clinical challenge in an ‘evidence-light’ area. Relevant case reports and guidelines were reviewed. In general, the withdrawal of immunosuppressive therapy is advised; however, a multidisciplinary, case-by-case approach is also emphasised. The patient’s lesion was removed and, following collaborative discussion, immunosuppression was continued post resection. This is thought to be the first reported case involving a Kaposi’s sarcoma in inflammatory bowel disease where immune therapy was not subsequently discontinued.

Pulmonary Kaposi's Sarcoma In Pregnancy

2004 ◽  
Vol 21 (6) ◽  
pp. 355-363 ◽  
Author(s):  
Ann E Bryant ◽  
Mehmet Genc ◽  
Rocío M Hurtado ◽  
Katherine T Chen
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document